Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509232 | 0.87 | EDNRA (0.47) | CYP2D6ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL19795862 | 0.87 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNATP53MEN1 | |
| SCHEMBL18012037 | 0.86 | CYP2D6 (0.59) | CYP2D6ALDH1A1LMNAMEN1POLB | |
| SCHEMBL4681142 | 0.86 | CYP2D6 (0.59) | CYP2D6ALDH1A1LMNAMEN1POLB | |
| SCHEMBL15676133 | 0.84 | CYP2D6 (0.41) | CYP2D6ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL15676135 | 0.84 | CYP2D6 (0.41) | CYP2D6ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL28734804 | 0.78 | BACE1 (0.61) | BACE1CYP2D6ALDH1A1MAPTLMNA | |
| SCHEMBL28734797 | 0.78 | BACE1 (0.61) | BACE1CYP2D6ALDH1A1MAPTLMNA | |
| SCHEMBL28734798 | 0.78 | BACE1 (0.61) | BACE1CYP2D6ALDH1A1MAPTLMNA | |
| SCHEMBL28734796 | 0.78 | BACE1 (0.61) | BACE1CYP2D6ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202340-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2016126572-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | GBA1, GBA2, GAA | BACE1 456/4885CYP2D6 3646/4885ALDH1A1 2367/4885 |
| US-10202340-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | GBA1, GBA2, GAA | BACE1 456/4885CYP2D6 3646/4885ALDH1A1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.